# US 2015/0087551 A1 · Methods and systems for sampling, screening, and diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0087551 A1
- Document ID: US20150087551A1
- Status: Published application
- Kind: A1
- Application number: 14/337,591
- Filed: 2014-07-22
- Published: 2015-03-26
- Earliest claimed: 2004-02-04
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Rolf U. Halden
- Web page: https://patentgrep.com/patent/US20150087551A1

## CPC

- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- B01L 3/5025: {for parallel transport of multiple samples}
- C12Q 1/24: Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
- C12Q 1/26: involving oxidoreductase
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/6818: {Sequencing of polypeptides}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- H01J 49/04: Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
- B01L 2200/0668: Trapping microscopic beads
- B01L 2300/0829: Multi-well plates; Microtitration plates
- B01L 2300/0838: Capillaries
- G01N 1/10: in the liquid or fluent state {(burettes, pipettes B01L3/02; sampling of ground water E02D1/06; metering by volume of fluids or fluent solid material G01F11/00, G01F13/00)}
- G01N 2333/90241: acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2500/10: involving cells
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- H01J: ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS (spark-gaps H01T; electric arc lamps H05B31/00; particle accelerators H05H)

## Abstract

Apparatus, systems, and methods for detecting, screening and sampling of cells are disclosed.

## Claims

### Claim 1

A system for characterizing cells present in an environment, the system comprising:
a) a collection device having a plurality of capillary microcosms for collecting or maintaining cells in the environment;
b) a sampling device for sampling cells present in the capillary microcosms; and
c) a characterizing device for characterizing the cells from the capillary microcosms;
wherein the sampling device is adapted to provide a plurality of samples to the characterizing device.

### Claim 2 (depends on 1)

The system of claim 1, wherein the collection device comprises:
i) a housing;
ii) an array of capillary microcosms within the housing; and
iii) a fluid manifold in fluid communication with the capillary microcosms for controllably providing a cell-containing fluid from the environment to the capillary microcosms, wherein the housing comprises an opening to controllably permit cells from the environment to access the array.

### Claim 3 (depends on 2)

The system of claim 2, wherein at least one of the capillary microcosms is provided with a substrate for trapping cells.

### Claim 4 (depends on 1)

The system of claim 1, wherein the collection device further comprises a pump for pumping fluid into the fluid manifold.

### Claim 5 (depends on 1)

The system of claim 1, wherein the collection device comprises at least one sensor for real-time monitoring of a condition within the collection device.

### Claim 6 (depends on 2)

The system of claim 2, wherein the array of capillary microcosms is configured for use with an automated sampling device.

### Claim 7 (depends on 6)

The system of claim 6, wherein the sampling device comprises an automated fluid handling device.

### Claim 8 (depends on 1)

The system of claim 1, wherein the sampling device further comprises means for performing sample clean-up.

### Claim 9 (depends on 1)

The system of claim 1, wherein the characterizing device comprises a mass spectrometer.

### Claim 10 (depends on 1)

The system of claim 1, wherein the cells are selected from the group consisting of prokaryoyes, eukaryotes, yeasts, fungi, bacteria, Archaea, parasites, protozoa, plant cells, and animal cells.

### Claim at position 11

11-22. (canceled)

### Claim 23

A method for optimizing medical treatment for a patient, the method comprising:
a) providing a device comprising a housing and an array of capillary microcosms, each of the capillary microcosms being in fluid communication with a fluid manifold, and each of the capillary chambers containing either i) a case sample associated with a disease state of the patient or ii) a control sample;
b) subjecting each of said case and control samples to a treatment condition;
c) determining the effect of the treatment condition on each sample; and
d) selecting an optimized medical treatment for the patient.

### Claim 24 (depends on 23)

The method of claim 23, wherein the treatment condition comprises treatment with a candidate pharmaceutical agent.

### Claim 25 (depends on 23)

The method of claim 23, wherein the control sample is a sample of normal tissue from the patient.

### Claim 26 (depends on 23)

The method of claim 23, wherein the case sample is a sample of diseased tissue from the patient.

### Claim 27

A method for screening medical treatments for a patient, the method comprising:
a) providing a device comprising a housing and an array of test chambers, each of the test chambers being in fluid communication with a fluid manifold, and each of the test chambers containing either i) a candidate pharmaceutical agent or ii) a control;
b) exposing each of said test chambers to a biological fluid of the patient; and
c) determining the effect of the candidate pharmaceutical agent on the biological fluid.

### Claim 28 (depends on 27)

The method of claim 27, further comprising:
d) selecting an optimized medical treatment for the patient.

### Claim 29 (depends on 27)

The method of claim 27, wherein the candidate pharmaceutical agent comprises an antibiotic, an antineoplastic agent, an antidiabetic agent, an anticoagulant agent, or a natural or synthetic nucleotide, polynucleotide, nucleotide mimetic, or polynucleotide mimetic.

### Claim 30 (depends on 29)

The method of claim 29, wherein the biological fluid is blood.

### Claim 31 (depends on 27)

The method of claim 27, wherein the device is implanted within the body of the patient.

### Claim 32 (depends on 27)

The method of claim 27, wherein the step of determining the effect of the candidate pharmaceutical agent on the biological fluid comprises determining the bioavailability, biodistribution, or metabolism of the candidate pharmaceutical agent in the biological fluid.

### Claim 33 (depends on 27)

The method of claim 27, wherein the step of determining the effect of the candidate pharmaceutical agent on the biological fluid comprises determining the antibiotic effect of a candidate pharmaceutical agent on a blood-borne pathogen.

### Claim 34

A method for diagnosing an infectious or parasitic disease condition, the method comprising:
a) providing a device comprising a housing and an array of test chambers, each of the test chambers being in fluid communication with a fluid manifold and being configured to trap an infectious microorganism or parasite;
b) exposing each of said test chambers to a biological fluid of the patient;
c) identifying a microorganism or parasite trapped in a test chamber.

### Claim 35 (depends on 34)

The method of claim 34, wherein the step of identifying comprises identifying a protein characteristic of the microorganism or parasite.

### Claim 36 (depends on 34)

The method of claim 34, wherein the protein is identified using mass spectrometry.

### Claim 37 (depends on 36)

The method of claim 36, wherein the protein is identified using multidimensional mass spectrometry.

### Claim 38

A method for testing an agent to determine an effect of the agent on a living organism, the method comprising:
a) providing a device comprising a housing and an array of capillary microcosms, each of the capillary microcosms being in fluid communication with a fluid manifold, and each of the capillary chambers containing either i) the agent to be tested or ii) a control;
b) subjecting each of said agent and control samples to a fluid environment representative of a living organism; and
c) determining the effect of the agent on the fluid environment.

### Claim 39

A method for detecting in a sample a microorganism having a pre-determined phenotype, the method comprising the steps of:
a) selecting a biomarker for the pre-determined phenotype;
b) providing a sample for testing;
c) detecting by mass spectroscopy the presence or absence of the biomarker diagnostic of a microorganism having the pre-determined phenotype in the sample.

### Claim 40 (depends on 39)

The method of claim 39, wherein the biomarker is an enzyme.

### Claim 41 (depends on 40)

The method of claim 40, wherein the enzyme is an oxygenase enzyme.

### Claim 42 (depends on 41)

The method of claim 41, wherein the oxygenase is a dioxygenase.

### Claim 43 (depends on 39)

The method of claim 39, wherein the step of detecting by mass spectroscopy comprises detecting an enzyme by peptide-mass fingerprinting.

### Claim 44 (depends on 43)

The method of claim 43, wherein the step of detecting is performed on a digest of whole cells.

### Claim 45 (depends on 39)

The method of claim 39, wherein the pre-determined phenotype is a phenotype useful for bioremediation.

### Claim 46 (depends on 39)

The method of claim 39, wherein the microorganism is Sphingomonas wittichii Strain RW1.

### Claim 47 (depends on 39)

The method of claim 39, wherein the microorganism is a parasite or pathogen.

### Claim 48 (depends on 39)

The method of claim 39, comprising the further step of inducing biomarker production in the microorganism before detecting the presence or absence of the biomarker.

### Claim 49 (depends on 39)

The method of claim 39, wherein the step of detecting by mass spectroscopy comprises detecting an enzyme by peptide sequencing using multi-dimensional mass spectrometry.
